HBM Holdings Limited has issued a positive profit alert, indicating an expected profit for the six months ending June 30, 2025, ranging from approximately US$68 million to US$74 million. This anticipated increase in profit is primarily attributed to ongoing strategic partnerships with global pharmaceutical companies, including a significant collaboration with AstraZeneca PLC. The forecast is based on a preliminary assessment of the Group's unaudited management accounts for the Reporting Period. Shareholders and potential investors are advised to exercise caution and seek professional advice when dealing in the company's securities, as the actual results may differ from this preliminary assessment. The official interim results announcement is expected to be published by the end of August 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。